On Monday, Ocular Therapeutix Inc (NASDAQ: OCUL) was 3.34% up from the session before settling in for the closing price of $8.69. A 52-week range for OCUL has been $3.24 – $11.77.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 121.20%. When this article was written, the company’s average yearly earnings per share was at -16.28%. With a float of $135.64 million, this company’s outstanding shares have now reached $156.65 million.
Let’s determine the extent of company efficiency that accounts for 267 employees. In terms of profitability, gross margin is 90.58%, operating margin of -230.12%, and the pretax margin is -284.02%.
Ocular Therapeutix Inc (OCUL) Breakdown of a Key Holders of the stock
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Ocular Therapeutix Inc stocks. The insider ownership of Ocular Therapeutix Inc is 13.72%, while institutional ownership is 77.39%. The most recent insider transaction that took place on Nov 25 ’24, was worth 26,561. In this transaction Chief Scientific Officer of this company sold 2,948 shares at a rate of $9.01, taking the stock ownership to the 269,059 shares. Before that another transaction happened on Nov 25 ’24, when Company’s Chief Development Officer sold 2,897 for $9.01, making the entire transaction worth $26,102. This insider now owns 213,087 shares in total.
Ocular Therapeutix Inc (OCUL) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.25 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -16.28% per share during the next fiscal year.
Ocular Therapeutix Inc (NASDAQ: OCUL) Trading Performance Indicators
You can see what Ocular Therapeutix Inc (OCUL) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 12.94. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 22.98.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.32, a number that is poised to hit -0.25 in the next quarter and is forecasted to reach -1.06 in one year’s time.
Technical Analysis of Ocular Therapeutix Inc (OCUL)
Looking closely at Ocular Therapeutix Inc (NASDAQ: OCUL), its last 5-days average volume was 0.79 million, which is a drop from its year-to-date volume of 1.78 million. As of the previous 9 days, the stock’s Stochastic %D was 13.01%. Additionally, its Average True Range was 0.53.
During the past 100 days, Ocular Therapeutix Inc’s (OCUL) raw stochastic average was set at 42.19%, which indicates a significant increase from 22.56% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 57.44% in the past 14 days, which was higher than the 55.84% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $10.04, while its 200-day Moving Average is $8.21. However, in the short run, Ocular Therapeutix Inc’s stock first resistance to watch stands at $9.16. Second resistance stands at $9.35. The third major resistance level sits at $9.60. If the price goes on to break the first support level at $8.72, it is likely to go to the next support level at $8.47. Now, if the price goes above the second support level, the third support stands at $8.28.
Ocular Therapeutix Inc (NASDAQ: OCUL) Key Stats
There are 157,217K outstanding shares of the company, which has a market capitalization of 1.41 billion. As of now, sales total 58,440 K while income totals -80,740 K. Its latest quarter income was 15,430 K while its last quarter net income were -36,490 K.
